Assessment the effect of a drug in the treatment of abdominal pain in childre

Phase 2

Conditions: Functional abdominal pain.
Other and unspecified abdominal pain
R10.4

Registration Number: IRCT20190304042914N1

Lead Sponsor: Babol University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 64

Inclusion Criteria

FAP diagnosis based on Rome III criteria

Exclusion Criteria

Immunodeficiency
Consumption of probiotics or prebiotics within 7 days before participating in the study
Chronic underlying disease
Malignancy
The presence of red flags includes a pain that awakens the baby
Continuous pain of RUQ or RLQ
Vomiting (biliary, frequent, periodic, or disturbing for the physician)
Fever without cause
Urogenital Symptoms
Dysphagia
Severe chronic diarrhea or Nocturnal diarrhea
Gastrointestinal bleeding
Unwanted weight loss
Downtrend in the growth curve
Delayed puberty
Family history of IBD
Celiac and PUD
Localized tenderness in RUQ or RLQ
Localized mass
Splenomegaly
Jaundice
CVA tenderness
Arthritis
Vertebral tenderness
Disease in the perianal area
Abnormal or unreasonable findings in the examination
Hematochezia
Anemia
Hepatomegaly
Antibiotic use in the last month

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of pain. Timepoint: At the beginning of the study and one month after the start of treatment. Method of measurement: check list.

Secondary Outcome Measures

Name	Time	Method
umber of absentee days from school. Timepoint: At the beginning of the study and one month after the start of treatment. Method of measurement: Check list.;Pain intensity. Timepoint: At the beginning of the study and one month after the start of treatment. Method of measurement: Face scaling.